← All candidates
53 insider filings on record.
53 filings on record.
PCRXPacira BioSciences, Inc.
NasdaqGS · Healthcare · $1.05B
$24.68
-2.68% · Sep 14
53 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 9 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.05B
Float
36.2M
91% public
Short % float
Pro
Price / profit
75.3
Price / future profit
7.6
Price / sales
1.4
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
48 more transactions on Pro →Context
Wall St
$29.67 avg target
+20.2% vs today · 6 analysts · consensus Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26$0.60 act+$0.04
Q4 '25$0.57 act−$0.33
Q3 '25$0.70 act+$0.05
Q2 '25$0.74 act+$0.03
Coverage
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the DetailsInsider Monkey · 05-27Pacira BioSciences' (NASDAQ:PCRX) Performance Is Even Better Than Its Earnings SuggestSimply Wall St. · 05-13Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World DataSimply Wall St. · 05-03Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YZacks · 05-01
The file stays open
53 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice